CVS Health Corp.
CVSLast close · Oct 16, 202692.36−0.22 (−0.24%)
Market cap$118.1B
Between Mar 31, 2026 and Jun 26, 2026, CVS Health (CVS) insiders filed 40 Form 4 transactions: 9 sales worth $359.0M in total and no open-market purchase. The largest seller was Robbins Larry, $187.3M. 31 other filings were grants, exercises or gifts, which say nothing about buying or selling.
40
0
9
0
Form 4 transactions
| Date | Insider | Title | Code | Plan | Shares | Price | Value |
|---|---|---|---|---|---|---|---|
| 2026-06-26 | Clark James David | SVP, Cont & Chief Acct Officer | F | 454 | 90.98 | $41,304.9 | |
| 2026-05-31 | Newman Brian | EVP, Chief Financial Officer | F | 2,478 | 90.98 | $225,448.4 | |
| 2026-05-31 | Compton-Phillips Amy | EVP, Chief Medical Officer | F | 7,618 | 90.98 | $693,085.6 | |
| 2026-05-20 | AGUIRRE FERNANDO | Director | D | 30,437 | 93.78 | $2.9M | |
| 2026-05-21 | AGUIRRE FERNANDO | Director | D | 1,563 | 93.50 | $146,142.1 | |
| 2026-05-19 | ROBBINS LARRY | Director | S | 2M | 94.45 | $187.3M | |
| 2026-05-19 | ROBBINS LARRY | Director | S | 151 | 95.18 | $14,372.2 | |
| 2026-05-20 | ROBBINS LARRY | Director | S | 797,628 | 93.48 | $74.6M | |
| 2026-05-20 | ROBBINS LARRY | Director | S | 152,691 | 94.81 | $14.5M | |
| 2026-05-20 | ROBBINS LARRY | Director | S | 66,881 | 95.67 | $6.4M | |
| 2026-05-20 | ROBBINS LARRY | Director | S | 800 | 96.28 | $77,025.5 | |
| 2026-05-21 | ROBBINS LARRY | Director | S | 370,462 | 93.45 | $34.6M | |
| 2026-05-21 | ROBBINS LARRY | Director | S | 378,000 | 93.31 | $35.3M | |
| 2026-05-14 | Gallina John E | Director | A | 1,448 | 97.15 | $140,625 | |
| 2026-05-14 | Mahoney Michael F | Director | A | 1,737 | 97.15 | $168,750 | |
| 2026-05-14 | AGUIRRE FERNANDO | Director | A | 1,563 | 97.15 | $151,845.5 | |
| 2026-05-14 | Balser Jeffrey R. | Director | A | 2,058 | 97.15 | $199,934.7 | |
| 2026-05-14 | KIRBY J SCOTT | Director | A | 1,447 | 97.15 | $140,576.1 | |
| 2026-05-14 | Norwalk Leslie V | Director | A | 1,447 | 97.15 | $140,576.1 | |
| 2026-05-14 | SANSONE GUY P | Director | A | 1,447 | 97.15 | $140,576.1 | |
| 2026-05-14 | DECOUDREAUX ALECIA A | Director | A | 1,448 | 97.15 | $140,625 | |
| 2026-05-14 | Finucane Anne A. | Director | A | 1,544 | 97.15 | $150,000 | |
| 2026-05-14 | BROWN C DAVID II | Director | A | 1,544 | 97.15 | $149,999.6 | |
| 2026-05-14 | Shulman Douglas H. | Director | A | 1,448 | 97.15 | $140,625 | |
| 2026-05-14 | ROBBINS LARRY | Director | A | 1,930 | 97.15 | $187,500 | |
| 2026-05-08 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | S | 69,551 | 89.58 | $6.2M | |
| 2026-03-31 | Shah Prem S | EVP and Group President | A | 25,062 | 71.82 | $1.8M | |
| 2026-04-01 | Shah Prem S | EVP and Group President | F | 1,484 | 72.49 | $107,575.2 | |
| 2026-03-31 | Shah Prem S | EVP and Group President | A | 161,676 | 71.82 | $11.6M | |
| 2026-03-31 | Newman Brian | EVP, Chief Financial Officer | A | 19,493 | 71.82 | $1.4M | |
| 2026-03-31 | Newman Brian | EVP, Chief Financial Officer | A | 125,748 | 71.82 | $9.0M | |
| 2026-03-31 | Nelson Steven H | EVP and President, Aetna | A | 22,277 | 71.82 | $1.6M | |
| 2026-04-01 | Nelson Steven H | EVP and President, Aetna | F | 2,432 | 72.49 | $176,295.7 | |
| 2026-03-31 | Nelson Steven H | EVP and President, Aetna | A | 143,712 | 71.82 | $10.3M | |
| 2026-03-31 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | A | 22,277 | 71.82 | $1.6M | |
| 2026-04-01 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | F | 3,634 | 72.49 | $263,428.7 | |
| 2026-03-31 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | A | 143,712 | 71.82 | $10.3M | |
| 2026-03-31 | Khichi Samrat S. | EVP, CPO and General Counsel | A | 12,531 | 71.82 | $899,976.4 | |
| 2026-04-01 | Khichi Samrat S. | EVP, CPO and General Counsel | F | 3,541 | 72.49 | $256,687.1 | |
| 2026-03-31 | Khichi Samrat S. | EVP, CPO and General Counsel | A | 80,838 | 71.82 | $5.8M |
Codes are the SEC's: P open-market purchase, S open-market sale; M exercise, F tax withholding, A grant and G gift are routine. A 10b5-1 flag means the trade ran under a plan adopted in advance. Method notes in where the numbers come from.